Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Nippon Shinyaku Licenses Prulifloxacin to Lee's Pharma in China
March 16, 2009
- Studies on Ethnic Differences between Japan, China and South Korea Progress
March 16, 2009
- Teijin, Nissan Chemical License NTC-801 to BMS
March 16, 2009
- Cancer Treatment Using Unapproved Peptide Vaccine Applied for as Advanced Medical Technology
March 16, 2009
- Bristol-Myers to Promote Sprycel with Over 200 MRs
March 16, 2009
- More Objective Endpoints Needed for Allergic Rhinitis Treatments
March 16, 2009
- 2008 Ethical Drug Market in Japan Totaled ¥8,254.3 Bil. on NHI Price Basis: IMS
March 16, 2009
- R&D NEWS IN BRIEF
March 16, 2009
- Astellas Files Lawsuit against CVT
March 16, 2009
- Ortho-K Recommended for Approval
March 16, 2009
- Olmetec Remains No. 1 for 2nd Month Running on Both GP and HP Markets: Rep Track Survey
March 16, 2009
- Takara Bio to Launch Reagent to Prepare Human iPS Cells
March 16, 2009
- Nat'l Univ. Hospitals to Consider Joint Purchase of Drugs
March 16, 2009
- New Sales System May Adversely Affect Business in Short Term: Mr Yamada of Rohto
March 16, 2009
- BUSINESS NEWS IN BRIEF
March 16, 2009
- Diclofenac-Based OTC Drugs Recommended for Approval
March 16, 2009
- FDA to Require New Clinical Data on Alogliptin: Takeda
March 16, 2009
- Pro-Online Sale Parties Exchange Opinions
March 16, 2009
- Clozaril Recommended for Approval under Strict Monitoring System
March 16, 2009
- Acquisition of Wyeth to Make Pfizer No. 1 in Japan: Mr Iwasaki
March 16, 2009
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…